|
[1]Shepared CW, Finelli L, Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancent Infect Dis, 2005, 5:558-567.
|
|
[2]Zeuzem S, Poordad F.Pegylated-interferon plus ribavirin therapy in the treatment of CHC:individualization of treatment duration according to on-treatment virologic response[J].Curr Med Res Opin, 2010, 26 (7) :1733-1743.
|
|
[3]Yu CI, Chiang BL.A new insight into hepatitis C vaccine development[J].J Biomed Biotechnol, 2010, 2010:548280.Epub 2010 Jun 13.
|
|
[4]Stoll-Keller F, Barth H, Fafi-Kremer S, et al.Development of hepatitis C virus vaccines:challenges and progress[J].Expert Rev Vaccines, 2009, 8 (3) :333-345.
|
|
[5]Law M, Maruyama T, Lewis J, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J].Nature Medicine, 2008, 14 (1) :25-27.
|
|
[6]Forns X, Payette PJ, Ma X, et al.Vaccination of ch-impanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV[J].Hepatology, 2000, 32 (3) :618-625.
|
|
[7]Dahari H, Feinstone SM, Major ME.Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins[J].Gastroenterology, 2010, 139 (3) :965-974.
|
|
[8]Frey SE, Houghton M, Coates S, et al.Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults[J].Vaccine, 2010, 28 (38) :6367-6373.
|
|
[9]Bowen DG, Walker CM.Adaptive immune responses in acute and chronic hepatitis C virus infection[J].Nature, 2005, 436 (7053) :946-952.
|
|
[10]Thimme R, Bukh J, Spangenberg HC, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci U S A, 2002, 99 (24) :15661-15668.
|
|
[11]Dazert E, Neumann-Haefelin C, Bressanelli S, et al.Loss of viral fitness and cross-recognition by CD8+T cells limit HCV escape from a protective HLA-B27-restricted human immune response[J].J Clin Investi, 2009, 119 (2) :376-386.
|
|
[12]Smyk-Pearson S, Tester IA, Klarquist J, et al.Spontaneous recovery in acute human hepatitis C virus infection:functional T-cell thresholds and relative importance of CD4 help[J].J Virol, 2008, 8 (24) :1827-1837.
|
|
[13] Semmo N, Day CL, Ward SM, et al.Preferential loss of IL-2-secreting CD4+T helper cells in chronic HCV infection[J].Hepatology, 2005, 41 (5) :1019-1028.
|
|
[14]Shoukry NH, Cawthon AG, Walker CM.Cell-mediated immunity and the outcome of hepatitis C virus infection[J].Annu Revi Microbiol, 2004, 58:391-424.
|
|
[15]Urbani S, Amadei B, Fisicaro P, et al.Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviralmemory CD8 responses[J].Hepatology, 2006, 44 (1) :126-139.
|
|
[16]Stamataki Z, Grove J, Balfe P, et al.Hepatitis C virus entry and neutralization[J].Clin Liver Dis, 2008, 12 (3) :693-712.
|
|
[17]Bustin LB, Rice CM.Flying under the radar:the im-munobiology of hepatitis C[J].Annu Rev Immunol, 2007, 25:71-99.
|
|
[18]Limmer A, Ohl J, Kurts C, et al.Efficient presentation of exogenous antigen by liver endothelial cells to CD8+T cells results in antigen-specific T-cell Tolerance[J].Nat Med, 2000, 6:1348-1354.
|
|
[19]Racanelli V, Rehermann B.The liver as an immunological organ[J].Hepatology, 2006, 43 (2 Suppl 1) :s54-62.
|
|
[20]GM Lauer, E Barnes, M Lucas, et al.High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection[J].Gastroenterology, 2004, 127 (3) :924-936.
|
|
[21]Firbas C, Boehm T, Buerger V, et al.Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine[J].Vaccine, 2010, 28 (12) :2397-2407.
|
|
[22]Yutani S, Komatsu N, Shichijo S, et al.Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-J Clini Hepatol, January 2011, Vol.27, No.1class I-A alleles[J].Cancer Science, 2009, 100 (10) :1935-1942.
|
|
[23]Yutani S, Yamada A, Yoshida K, et al.Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy[J].Vaccine, 2007, 25 (42) :7429-7435.
|
|
[24]Yu H, Huang H, Xiang J, et al.Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3[J].J Gen Virol, 2006, (87) :1-10.
|
|
[25]Gao M, Wang HP, Wang YN, et al.HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4 (+) Th1 cell responses in vivo[J].Vaccine, 2006, 24 (26) :5491-5497.
|
|
[26]BacardíD, Amador-Ca-izares Y, Cosme K.Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus[J].Hum Exp Toxicol, 2009, 28 (8) :479-491.
|
|
[27]冯志华, 周永兴, 焦成松, 等.Th1类细胞因子对pHCV-C重组体诱生免疫应答的增强作用[J].中国病毒学杂志, 2001, 16 (2) :101-104.
|
|
[28]Fournillier A, Gerossier E, Evlashev A, et al.An ac-celerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses[J].Vaccine, 2007, 25 (42) :7339-7353.
|
|
[29]Habersetzer F, Zarski JP, Leroy V, et al.A novel vectori-zed HCV therapeutic vaccine (TG4040) :results of a phase I study in naive patients chronically infected by HCV in Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver (EASL'09) [R].Copenhagen, Denmark, April 2009.
|
|
[30]Larsson M.The dendritic cell:the immune system's adjuvant--a strategy to develop a HCV vaccine?[J].Gastroenterology, 2006, 130 (2) :603-606.
|
|
[31]Koido S, Tanaka Y, Tajiri H, et al.Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells[J].Vaccine, 2007, 25 (14) :2610-2619.
|
|
[32]Anderson MJ, Shafer-Weaver K, Greenberg NM, et al.Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer[J].J Immunol, 2007, 178 (3) :1268-1276.
|
|
[33]Vietheer PT, Boo I, Drummer HE, et al.Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies[J].Antivir Ther, 2007, 12 (4) :477-487.
|
|
[34]Cheong WS, Drummer HE, Netter HJ.Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix[J].J Virol Methods, 2009, 158 (1-2) :35-40.
|
|
[35]Wei SH, Yin W, An QX, et al.A novel HCV vaccine approach using recombinant BCG expressing multi-epitope antigen[J].Archieve of viology, 2008, 153 (6) :1021-1029.
|
|
[36]郝春秋, 冯志华, 贾战生, 等.复制缺陷型HCV C基因腺病毒表达载体的构建包装及鉴定[J].世界华人消化杂志, 2003, 11 (2) :144-147.
|
|
[37] 周云, 李端, 陈琳, 等.HCV多CTL表位树突状细胞疫苗的构建及体外刺激T细胞反应[J].临床肝胆病杂志, 2011, 27 (1) :40-44.
|
|
[38]Li W, Li J, Tyrrell DL, et al.Expression of hepatitis C virus-derived core or NS3 antigens in human dendritic cells leads to induction of pro-inflammatory cytokines and normal T-cell stimulation capabilities[J].J Gen Virol, 2006, 87 (Pt 1) :61-72.
|
|
[39]Firbas C, Jilma B, Tauber E, et al.Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine:a randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J].Vaccine, 2006, 24 (20) :4343-4353.
|
|
[40]Vider-Shalit T, Raffaeli S, Louzoun Y.Virus-epitope vaccine design:informatic matching the HLA-I polymorphism to the virus genome[J].Mol Immunol, 2007, 44 (6) :1253-1261.
|
|
[41]Day CL, Lauer GM, Robbins GK, et al.Broad specificity of virus specific CD4+T helper cell responses in resolved hepatitis C virus infection[J].J Virol, 2002, 76 (24) :12584-12595.
|
|
[42]韦三华, 尹文, 雷迎峰, 等.HCV多表位基因重组BCG的筛选及其诱导的免疫应答研究[J].中华微生物学和免疫学杂志, 2007, 27 (11) :1041-1045.
|
|
[43]Li D, Xie YW, Jia ZS.Forecasting of hepatitis C virus CTL epitopes and design of multi-epitopes vaccine[J].Zhonghua Gan Zang Bing Za Zhi, 2009, 17 (10) :786-787.
|
DownLoad: